Arrowhead Pharmaceuticals is in discussions with health regulators to initiate clinical trials evaluating ARO-MAPT in patients with MAPT-associated frontotemporal dementia and progressive supranuclear palsy.

From the articleArrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data dropAlso in Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit